India's Sun Pharma senior executives swap leadership roles

Chutes and Ladders

Mumbai-based Sun Pharmaceutical Industries has named Kal Sundaram CEO for India and emerging markets for the country's top drugmaker, while Abhay Gandhi was named head of the company's North American division, the Indian Express newspaper reported.

The new roles are an indirect swap of responsibilities, with Sundaram coming back from the U.S. at the start of next year from his job as head of Taro Pharmaceutical Industries, which Sun bought in 2010 from its Israel-based founders. Gandhi previously held the post of CEO of Sun's India and subcontinent business.

Sun founder and Managing Director Dilip Shanghvi remains in control of the firm. Last year, he embarked on a major consolidation effort following the purchase of Ranbaxy Laboratories that included fresh looks at manufacturing operations hit by quality and data issues highlighted by the U.S. FDA


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In earnings for the year ended March 31, released in May, Sun--the world's fifth largest generics maker--said it was confident a massive reorganization to consolidate operations after its purchase of Ranbaxy Laboratories in 2014 were "on track."  In particular, the company lauded progress in the U.S. market.

- here's the story from the Indian Express

Related Articles:
India's Sun brings home Taro CEO as business plan accelerates


Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.